Shop by Category

  • Services
  • ADC and Other Drug Conjugates (ODC)
  • AqT® ADC Dual Labeling Kits and Products
  • Antibody
  • Biotinylation
  • Streptavidin/Avidin
  • Digoxigenin Labeling
  • Enzyme
  • Fluorescent Dye Labeling
  • Nucleic Acid and Oligo
  • Peptide
  • Protein
  • Small Molecule
  • Standards and Controls
  • Assay, Buffers and Others
  • Membrane Protein and GPCR Related
  • Solid Support

    • Shop by Brand

  • PerKit®
  • SepSphere™
  • AqT®
  • Routine Synthesis™
  • oxLink™
  • sxLink™
  • View all Brands

    • About Us

    CellMosaic® Inc. Is a Leader in Innovative Bioconjugation and Drug Delivery Solutions

    CellMosaic® is a Massachusetts-based technology company delivering high-quality, innovative bioconjugation solutions powered by its proprietary AqueaTether® (AqT®) Technologies and Advanced Conjugation Processes.

    Company Fact Sheet

    Bioconjugates are widely used as research tools, diagnostic reagents, and emerging therapeutic modalities, including antibody–drug conjugates (ADCs). Because of the inherent complexity of bioconjugation and the multidisciplinary expertise required across chemistry, biology, analytics, and manufacturing, relatively few companies can consistently deliver high-quality bioconjugation services and products.

    Founded in 2008 by Dr. Huang, CellMosaic was established to address this need by leveraging her extensive experience in bioconjugation, drug development, and manufacturing.

    Since its inception, CellMosaic has invested significantly in the development of Advanced Conjugation Processes and has developed more than 400 proprietary processes supported by validated manufacturing protocols and comprehensive quality control systems.

    Building on this foundation, CellMosaic has established a successful custom conjugation services business, completing more than 700 custom projects and producing more than 500 unique custom conjugates across diverse research and development fields as of February 2026.

    In late 2016, CellMosaic began commercializing its Personalized Conjugation Kit (PerKit®) platform. By December 2017, the PerKit® product line had expanded to include antibody–drug conjugate (ADC) kits and protein–drug conjugate (PDC) kits , enabling customers to prepare high-quality conjugates in-house using standardized procedures comparable to those used at CellMosaic.

    Frequently used chemicals, labeling reagents, and bioconjugates are also available through our reagent and product portfolio . As of February 2026, PerKit® and reagent products had been sold to more than 450 organizations in more than 33 countries worldwide.

    In 2011, CellMosaic initiated the development of a new class of linkers designed to address challenges associated with labeling and conjugating hydrophobic compounds. The company pioneered the use of natural sugar alcohols to create novel linker and polymer carrier systems known as AqueaTether® (AqT®) Technologies for bioconjugation and drug delivery.

    Development of this platform was supported in part by competitively awarded funding from the U.S. Department of Defense Breast Cancer Research Program Breakthrough Award from 2015 to 2018 and continues to advance through CellMosaic’s internal research and development programs.

    Based on AqT® Technology, CellMosaic has commercialized next-generation bioconjugation kits, reagents, and related products. The AqT® platform also supports the development of enhanced therapeutics across a broad range of drug modalities and indications, helping accelerate drug discovery and the optimization of drug candidates.

    Over the years, CellMosaic has developed additional proprietary technologies, including oxLink™ and sxLink™ for studying protein–protein interactions, supported by NIH SBIR funding, and NeIon™ for detecting and quantifying trace analytes by mass spectrometry. Selected products based on these technologies are available for research use.

    CellMosaic currently organizes its operations into four business units to meet customer demand for high-quality, innovative, and advanced bioconjugation solutions:

    1. Reagents and Kits
      Premade bioconjugates, labeled or modified molecules, reagents, and kits that enable customers to prepare bioconjugates in-house.
    2. R&D Bioconjugation Services
      Custom Bioconjugation Services and standardized bioconjugation services offered through our Routine Synthesis™ platform.
    3. Contract Development and Manufacturing Organization (CDMO) Services
      Process development, scale-up, and GLP/GMP manufacturing of bioconjugate therapeutics and diagnostic conjugates, including ADC development and manufacturing using clinically established classical linker technologies.
    4. AqT® ADC Development and Manufacturing
      Enabling customers to leverage AqT® linkers for next-generation ADC development and manufacturing .